News
Allon Therapeutics wins 2009 best small cap IR award
VANCOUVER — February 6, 2009 - Allon Therapeutics Inc. (TSX: NPC) announced today that its investor relations program has been ranked by IR Magazine’s survey of Canadian investors and analysts as the Best Overall Investor Relations Program for small-cap Canadian companies.
Allon’s award was accepted by Aaron Keay, Allon’s director of investor relations, at an awards banquet Thursday night at the Fairmont Royal York Hotel in Toronto. Keay joined Allon in 2005 and has led the investor relations program since then. He has a bachelor’s degree in human kinetics and commerce from the University of British Columbia.
Gordon McCauley, President and CEO of Allon, says the IR Magazine award is a validation of the Company’s commitment to accurate and effective communication with shareholders as well as Keay’s leadership of the program.
“We are very proud of the work that our team has done toward developing the first drugs to modify diseases like Alzheimer’s and frontotemporal dementia. It is also important to tell our story effectively. This award, based on the feedback from investors and analysts, is a big compliment to those efforts and Aaron’s leadership of the program” said McCauley.
IR Magazine’s survey was conducted by London, England-based Mary Maude Research using samples provided by Thomson Reuters and Equicom and additional data from TSX Group. The complete results of the survey will be published in IR magazine’s Investor Perception Study, Canada 2009.
The awards banquet was hosted in association with The Globe and Mail and co-sponsored by Barnes McInerney, Bell, Broadridge, Business Wire, CCR Solutions, CIBC Mellon, the Canadian Investor Relations Institute, CNSX Canadian National Stock Exchange, CNW Group, Computershare Georgeson, Laurel Hill Advisory Group, Marketwire, NASDAQ OMX, NYSE Euronext, otcQX, and Toronto Stock Exchange.
About Allon
Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon’s drug AL-108 has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer’s disease. Allon has Phase II human efficacy programs pursuing large underserved markets: Alzheimer's disease, frontotemporal dementia, and schizophrenia-related cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection CompanyTM) and based in Vancouver. For additional information please visit the Company's website: www.allontherapeutics.com.
Forward Looking Statements
Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management’s outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon’s dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon’s public filings at www. SEDAR.com and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements and Allon disclaims any obligation to update or announce changes in any such factors except in its periodic filings.
-30-
FOR FURTHER INFORMATION PLEASE CONTACT:
Allon Therapeutics Inc. - Investor and Media Contact
Aaron Keay
Director, Investor Relations
(604) 742-2540 or Cell: (604) 323-6911
Email: akeay@allontherapeutics.com
Website: www.allontherapeutics.com
